← Russell 3000 cross-section

SRZN Surrozen, Inc./DE

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$287m
Revenue TTM
$12m
Net income TTM
$-332m
Free cash flow
$-35m
Composite score
Sector rank
#2688

Valuation

P / E
EV / EBITDA
EV / sales
16.1
FCF yield
-12.18%
Earnings yield vs 10-yr
-120.34pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-2,885.3%
EBITDA margin
ROE
151.9%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-6.91m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Research Service Revenue – Related Party The decrease of $1.0 million in research service revenue – related party for three months ended June 30, 2026, compared to three months ended June 30, 2025, is attributable to the termination of the Research Collaboration Agreement with TCGFB, Inc., effective in November 2025. Research and Development Expenses The increase of $2.4 million, or 40%, in research and development expenses for the three months ended June 30, 2026, compared to the three months ended June 30, 2025, is primarily due to a $1.7 million increase in manufacturing costs, lab expenses and consulting fees for SZN-8141 and a $1.0 million increase in employee-related expenses primarily …Surrozen, Inc./DE, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →